
Using DataFax Standard Reports for Risk-Based Monitoring

Vaishali Krishnan

VA Palo Alto Cooperative Studies Program Coordinating Center



Presentation Roadmap

- Background
 - VA Cooperative Studies Program (CSP)
 - FDA guidance
- DataFax Standard Reports
- Monthly Data Quality Reports
- Site Performance Summary

VA Cooperative Studies Program (CSP)

VA Research and Development

- Plans and conducts large, multicenter clinical trials and epidemiological studies

- Mission:

To advance the health and care of veterans through cooperative research studies that produce innovative and effective solutions to veteran and national healthcare problems



U.S. Department
of Veterans Affairs





CSP, continued



- Five coordinating centers (CSPCCs), additional epi centers
- One pharmacy coordinating center
 - Assist with drug/device studies
 - Adverse Event and SAE specialists
 - CSP monitoring and auditing team (SMART)



CSP, continued



- Examples of current PA-CSPCC studies
 - Comparative effectiveness of psychotherapies
 - Steroid treatment for severe pneumonia
 - Stents

- CSP studies are typically
 - Not IND/IDE with an NDA/PMA
 - Not usually funded for 100% on-site monitoring

From the FDA Guidance: Risk-Based Approach to Monitoring (RBM)

- August 2013: “Oversight of Clinical Investigations – A Risk-Based Approach to Monitoring”
- Guidance’s goal: enhance human subject protection and quality of clinical trial data by focused sponsor oversight
- Modern approach, risk-based

FDA Guidance on RBM, continued

- Regulations require monitoring, but do not specify how to do so
- Clinical Trials Transformation Initiative (CTTI) survey: wide range of monitoring practices

FDA Guidance, continued

- Advocates a combination of monitoring activities to oversee a study effectively
- Encourages greater reliance on centralized monitoring methods (vs. on-site monitoring)
- Focuses on critical data elements to perform risk assessment and to inform monitoring plans

Centralized Monitoring

Information on critical study parameters is used to:

- Identify high risk sites
- Define escalation path to resolve deficiencies
- Focus limited resources

Examples of Centralized Monitoring (From the Guidance)

- Routine monitoring of data quality by review of database
 - Analyze performance metrics
-
- Conduct statistical analyses to identify unusual data trends
 - Source data verification via remote data access
 - Perform administrative and regulatory tasks and reviews

Monthly Data Quality Reports (MDQR)

- 15+ years at PA-CSPCC
- Patient and Center Tracking Reports → Graphs (via SAS, Excel, scripts, etc.)
- Screening and Enrollment Tables → Graphs
- Comparison across sites
- Not standardized across studies

DataFax Standard Reports

Patient & Center Tracking

Data Quality


- DF_PTmissing

Overdue visits and missing plates, by patient

- DF_CTcrfs: summary of forms received, by site

CENTER Number	ACTIVITY Patients	Visits	Records	MEAN # Fax In	DAYS FROM DB Entry	VISIT TO: DB Clean	% RECORDS On Arrival	CLEAN Now
334	9	327	1379	4.9	5.1	14.6	81.9	100.0
	4	126	969	20.7	21.0	43.0+	64.0	99.8
	9	457	2502	15.9	16.5	29.4+	78.3	99.8
	10	226	1208	112.4	112.9	175.3+	66.4	99.2
	17	532	3549	6.0	6.3	18.6+	84.8	99.9
	31	908	6691	2.7	3.4	9.7+	86.2	100.0


Monthly Data Quality Reports (MDQR)




From DF_CTqcs

Monthly Data Quality Reports


Figure 8
Average Days to Resolve QCs
As of [REDACTED]



From DF_CTqcs



From DF_CTcrfs



RBM: Monthly Site Performance Summary

- Standardized across studies
- Focused on site performance metrics
 - Suggested flagging thresholds for assigning risk status
 - High and medium alerts
 - Allows study team to adjust status for mitigating factors
- Categories (some flexibility within)
 - Administrative
 - Safety
 - Data integrity

RBM Escalation

- High-alert sites: clear escalation paths
 - Sponsor staff (DM, PM) work more closely with site
 - Center Director, Study Chair
 - Request extra on-site monitoring

SPS: Data Integrity Issues

CSP XXX			DATA ISSUES							
Date: 11/30/2012	Site Approval Date	Rand	Avg Days from Visit to Form Submissio	Total # of QCs	#, % Resolved QCs among all QCs		#, % of Unresolved QCs among all QCs		# of Unresolved QCs ≥ 30 days	# of Overdue 60-Day FU Visits
					#	%	#	%		
North Pole	01/19/2012	10	5	45	40	89	5	11	4	0
Sombertown	01/19/2012	6	10	83	80	96	3	4	0	0
Whoville	02/07/2012	14	3	99	40	40	59	60	32	2
Pottersville	01/30/2012	14	1	34	15	44	19	56	11	1
Bedford Falls	02/13/2012	3	3	12	5	42	7	58	0	0
Bailey Park	01/20/2012	12	4	39	4	10	35	90	2	0
Mt. Crumpit	09/02/2012	2	7	58	45	78	13	22	11	0
TOTAL	.	61								

DF_CTrfs

DF_CTqcs

DF_PTmissing



CSP RBM Pilot

- Extend from local to program-wide, work in progress
- Pilot underway for performance metrics
 - Proposed data integrity metrics
 - Rate of queries per x data elements
 - Percentage of unresolved queries
 - Average number of days from visit to form submission
 - Percentage of missing visits (of expected, for randomized patients)

Future Plans

- Layer in additional centralized monitoring, such as:
 - Data falsification detection methods
 - Remote monitoring
 - Standardization of Good Data Management Practices
- DF Reports?
 - Fine-tune usage of current reports, or use them to develop custom reports
 - DF_stats: untapped resource?

Sources and Resources

My thanks to:

- Jennifer Cockroft, Acting Associate Director of Quality, Palo Alto CSPCC
- Darlene Krueger, Director, SMART, Albuquerque CSP Pharmacy Coordinating Center
- Palo Alto CSPCC statistical programmers: Yajie Wang, Lan Zhao, Robert Chiang, Lauren Uyeda

Contact Info

Vaishali Krishnan

vaishali.krishnan@va.gov

650-493-5000, option "1", option "2", ext. 22554